Li‐Yuan Bai

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 712 citations · Full text

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

J.S. Chen, Chih‐Hung Hsu, Nai‐Jung Chiang et al. · Annals of Oncology · 2015 · 157 citations

Gastrointestinal Oncology, Medicine, Biliary Cancer +7

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Chia‐Lang Hsu, Da‐Liang Ou, Li‐Yuan Bai et al. · Liver Cancer · 2021 · 143 citations · Full text

RNA-Binding Protein Quaking, a Critical Regulator of Colon Epithelial Differentiation and a Suppressor of Colon Cancer

Guodong Yang, Haiyan Fu, Jie Zhang et al. · Gastroenterology · 2009 · 127 citations

Rna Binding Proteins, Colorectal Cancer, Pathology +9